Affimed (AFMD) News Today → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free AFMD Stock Alerts $4.35 +0.29 (+7.14%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 2:00 AM | americanbankingnews.comAffimed (NASDAQ:AFMD) Sees Large Increase in Short InterestJune 1 at 1:02 PM | globenewswire.comAffimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortMay 31 at 11:51 AM | marketbeat.comShort Interest in Affimed (NASDAQ:AFMD) Grows By 13.0%Affimed (NASDAQ:AFMD - Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 230,700 shares, an increase of 13.0% from the April 30th total of 204,100 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average daily trading volume, of 93,400 shares, the short-interest ratio is currently 2.5 days.May 31 at 1:44 AM | americanbankingnews.comAffimed (NASDAQ:AFMD) Given Consensus Recommendation of "Buy" by BrokeragesMay 31 at 1:44 AM | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Rating of "Buy" from BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has received an average recommendation of "Buy" from the five brokerages that are presently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that hMay 29, 2024 | msn.comAffimed gets FDA fast track status for AFM24 for EGFR lung cancerMay 29, 2024 | markets.businessinsider.comAffimed's AFM24 With Atezolizumab For EGFR Wild-Type NSCLC Gets FDA Fast Track Status; Stock UpMay 29, 2024 | globenewswire.comAffimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerMay 28, 2024 | globenewswire.comAffimed Announces Annual General Meeting of ShareholdersMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 24, 2024 | americanbankingnews.comAffimed (NASDAQ:AFMD) Shares Pass Below Two Hundred Day Moving Average of $5.23May 23, 2024 | globenewswire.comAffimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024May 17, 2024 | investorplace.comSmall-Cap Sensations: 3 Stocks Under $10 With 10X PotentialMay 14, 2024 | globenewswire.comAffimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressApril 24, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 24, 2024 | globenewswire.comAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyApril 11, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Recommendation of "Buy" from BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has been assigned an average rating of "Buy" from the five analysts that are covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issuApril 4, 2024 | marketbeat.comFY2024 EPS Estimates for Affimed (NASDAQ:AFMD) Lifted by Cantor FitzgeraldAffimed (NASDAQ:AFMD - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 earnings estimates for Affimed in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the biopharmaceutical company wilApril 3, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Expected to Earn FY2028 Earnings of ($0.92) Per ShareAffimed (NASDAQ:AFMD - Free Report) - Stock analysts at HC Wainwright issued their FY2028 earnings estimates for Affimed in a research note issued to investors on Monday, April 1st. HC Wainwright analyst S. Ramakanth expects that the biopharmaceutical company will earn ($0.92) per share for the yApril 1, 2024 | markets.businessinsider.comPromising Clinical Trials and Strategic Financial Management Affirm Buy Rating for AffimedApril 1, 2024 | finance.yahoo.comAffimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call TranscriptApril 1, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Price Target Cut to $25.00Wells Fargo & Company lowered their price target on shares of Affimed from $30.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday.April 1, 2024 | marketbeat.comAffimed's (AFMD) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a research note on Monday.April 1, 2024 | marketbeat.comShort Interest in Affimed (NASDAQ:AFMD) Grows By 10.6%Affimed (NASDAQ:AFMD - Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 171,600 shares, a growth of 10.6% from the February 29th total of 155,100 shares. Currently, 1.3% of the company's shares are short sold. Based on an average trading volume of 99,600 shares, the short-interest ratio is presently 1.7 days.March 31, 2024 | markets.businessinsider.comBuy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial PositionMarch 31, 2024 | gurufocus.comQ4 2023 Affimed NV Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comHere's what Wall Street expects from Affimed's earningsMarch 28, 2024 | investorplace.comAFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023March 28, 2024 | globenewswire.comAffimed Reports 2023 Financial Results and Operational ProgressMarch 27, 2024 | benzinga.comA Preview Of Affimed's EarningsMarch 21, 2024 | globenewswire.comAffimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024March 20, 2024 | marketbeat.comAffimed (AFMD) Scheduled to Post Earnings on ThursdayAffimed (NASDAQ:AFMD) will be releasing earnings on Thursday, March 21, Yahoo Finance reports.March 13, 2024 | seekingalpha.comJefferies starts Cue at buy, cites partnering potentialMarch 12, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Sees Strong Trading VolumeAffimed (NASDAQ:AFMD) Sees Large Volume IncreaseMarch 11, 2024 | marketbeat.comTrading was temporarily halted for "AFMD" at 07:03 PM with a stated reason of "News pending."March 8, 2024 | msn.comWhy Is Affimed (AFMD) Stock Moving Today?March 8, 2024 | investorplace.comWhy Is Affimed (AFMD) Stock Moving Today?March 7, 2024 | msn.comVaxxinity gains after early-stage data for Parkinson’s disease drugMarch 6, 2024 | finanznachrichten.deAffimed N.V.: Affimed Announces 1-for-10 Reverse Stock SplitMarch 6, 2024 | msn.comAffimed falls on 1-for-10 reverse stock splitMarch 6, 2024 | investorplace.com7 of the Best Speculative Stocks You Can Snag for Less Than $1March 6, 2024 | globenewswire.comAffimed Announces 1-for-10 Reverse Stock SplitFebruary 14, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Sees Large Decrease in Short InterestAffimed (NASDAQ:AFMD - Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 1,320,000 shares, a drop of 17.0% from the January 15th total of 1,590,000 shares. Based on an average trading volume of 1,080,000 shares, the days-to-cover ratio is currently 1.2 days.February 14, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Shares Pass Above 50 Day Moving Average of $0.53Affimed (NASDAQ:AFMD) Stock Crosses Above 50-Day Moving Average of $0.53February 6, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Stock Passes Above Fifty Day Moving Average of $0.52Affimed (NASDAQ:AFMD) Shares Pass Above Fifty Day Moving Average of $0.52January 9, 2024 | marketwatch.comAffimed CEO Adi Hoess Steps Down; Co to Cut Up to 50% of WorkforceJanuary 9, 2024 | finanznachrichten.deAffimed N.V.: Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerJanuary 8, 2024 | marketwatch.comAffimed N.V. to Expand Cohort in Study of AFM24 Following Promising DataJanuary 8, 2024 | finance.yahoo.comAffimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerJanuary 8, 2024 | finance.yahoo.comAffimed Announces Leadership Change and Organizational Restructuring Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Kiss of death from Joe Biden (Ad)I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care. I have uncovered a bombshell that changes everything… and threatens everything. AFMD Media Mentions By Week AFMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AFMD News Sentiment▼0.380.75▲Average Medical News Sentiment AFMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AFMD Articles This Week▼111▲AFMD Articles Average Week Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ENTA News Today XBIT News Today IMMP News Today EBS News Today ME News Today DSGN News Today ACRV News Today FHTX News Today ALDX News Today TSVT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AFMD) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
